| Identification | Back Directory | [Name]
Surinabant | [CAS]
288104-79-0 | [Synonyms]
SR147778
SR-147778
SR 147778
Surinabant
5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
1H-Pyrazole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-1-piperidinyl-
1-(2,4-Dichlorophenyl)-5-(4-bromophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide | [Molecular Formula]
C23H23BrCl2N4O | [MDL Number]
MFCD09970803 | [MOL File]
288104-79-0.mol | [Molecular Weight]
522.26 |
| Hazard Information | Back Directory | [Uses]
Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism[1][2]. | [Definition]
ChEBI: 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide is a member of pyrazoles and a ring assembly. | [References]
[1] Klumpers LE, et al. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol. 2013 Jul;76(1):65-77. DOI:10.1111/bcp.12071
[2] Fischler PV, et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022 Oct 3;13:927703. DOI:10.3389/fphar.2022.927703 |
|
| Company Name: |
GZanlihe
|
| Telephone: |
13928234501 18098185186 |
| Website: |
|
|